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Figure 1 Indicative treatment time comparisons 
 
Conclusions: Co-57 is a viable option for future development 
as a HDR radionuclide while Gd-153 will have limited uses for 
LDR or PDR. Of the commercially available sources little 
differences are observed between Co-60 and Ir-192 physically 
and clinically. The economic benefit of Co-60 is the greatest 
difference but other factors influence the choice of HDR 
equipment over and above the costs for most centres. 
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Purpose/Objective: Brachytherapy of intraocular tumors 
with 125I eye plaques has become a successful treatment 
modality and a viable alternative to enucleation. Plaque 
Simulator (PS) is an eye plaque treatment planning system 
(TPS) that uses TG-43 dosimetry. We aimed to verify the 
performance of the PS routinely used to plan patients having 
intraocular tumors. 
Materials and Methods: Relative dose distributions, including 
central axis depth dose and off axis dose profiles of 
Collaborative Ocular Melanoma Study (COMS) plaques with 
14, 16, 18 and 20 mm in diameter, loaded with model I25.S16 
seeds were measured using 1x1x1 mm3 Thermo Luminesans 
Dosimetry (TLD) cubes and computed using MCNP5 Monte 
Carlo code and Plaque Simulator (PS) TPS. Measurements and 
calculations were compared by normalizing 5 mm distance at 
the central axis of the plaque i.e COMS point. 
Results: For the central axis depth doses, the agreement 
between the measured and calculated dose distributions was 
within 13%, whereas deviations up to 22% were observed in 
single points far off-axis. For central axis dose distribution, 
the max difference among the PS, TLD and MCNP5 results was 
seen at 2 mm from the plaque center for all plaque sizes. For 
off axis dose distribution the maximum dose difference 
among the PS, TLD and MCNP5 results were seen at ± 12 mm 
from the central axis, periphery of the plaque. 
Conclusions: The Bebig Plaque Simulator is a reliable TPS for 
calculating relative dose distributions around realistic 
multiple 125I seed configurations if one understands its 
limitations at the first few milimeters around the plaque 
center and far off axis points. 
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Purpose/Objective: Purpose of this study was to verify the 
spatial dose distribution around a single iridium source using 
dosimetric films and compare the designated distribution 
with data generated by the treatment planning system (TPS). 
The secondary goal was to determine whether such 
measurements may be used to commission model based dose 
calculation algorithms (MBDCA). 
Materials and Methods: To determine the spatial distribution 
dose around the radioactive source radiochromic films MD-55 
were irradiated. Films during irradiation procedure were 
placed at different depths in the phantom and in the 
opposite orientation to the long axis of the source. Measured 
dose distribution has been checked and compared with the 
calculated spatial distribution of dose generated in the 
treatment planning system. The dose calculation has been 
performed according to the TG43 report. To compare two 
images presenting absorbed dose (measured and planned) 
analysis gamma factor has been used. 
Results: Comparison of the measured doses distribution and 
the corresponding dosegrids from TPS has showed that dose 
distribution around source may be measured using 
radiochromic films in certain dose range. The few areas of 
the images showed deviations from the acceptance criteria, 
mainly because of defects of films. 
 
Conclusions: The best matching of the measured and 
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calculated doses were obtained for a considerable distance 
from the edge of the film. Obtained results differences are 
minor. Radiochromic films seem to be a fair method to verify 
spatial dose distribution with high resolution. This method 
seem to be useful to evaluate introduced MBDCA in 
brachytherapy.  
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Purpose/Objective: Radiochromic film is a valuable 
dosimeter in brachytherapy used for dosimetry audit or QC. 
However, the water-equivalence of film and any resulting 
dose perturbation when used with Ir-192 and Co-60 HDR 
sources has not been sufficiently studied. The need for 
sufficiently large phantoms for full-scatter is understood, but 
an optimum phantom size for practical transport for audit 
measurements for both Ir-192 and Co-60, with appropriate 
correction factors, has not been determined. We address 
both issues using Monte Carlo derived correction factors. This 
work was undertaken for an IPEM brachytherapy audit in the 
UK, and will be of value for others conducting brachytherapy 
film dosimetry measurements or conducting Monte Carlo 
calculations in brachytherapy. 
Materials and Methods: MCNP5 code and Ir-192 and Co-60 
HDR source models were initially validated by comparing 
radial dose with consensus data. Due to small scale 
geometries, *F8 tally with full photon and electron transport 
was used, with 1E9 particle histories. Gafchromic EBT3 film 
chemical composition and geometry were modelled and 
calculations made to determine any dose perturbation due to 
the film compared to a uniform water case. A separate 
geometry was constructed to study scatter corrections at 
distances 20 to 75 mm from Ir-192 and Co-60 sources within 
water spheres of 100 to 600 mm radius, and equivalent 
cubes. An optimum phantom size for brachytherapy 
dosimetry audit was proposed. 
Results: For both Ir-192 and Co-60, there was negligible 
percentage change in dose due to the presence of a 15 mm 
strip of Gafchromic EBT3 film, shown in Table 1, confirming 
its ‘water equivalence’ for HDR brachytherapy dosimetry 
measurements. 
MCNP5 derived phantom scatter correction factors for Ir-192 
and Co-60 are provided in Figure 1. There is agreement 
within 0.1% with data for Ir-192 calculated by Perez-
Calatayud et al. (Med. Phys. 2004). A water phantom cube of 
side length 400 mm was considered optimum for 
brachytherapy dosimetry audit measurements, requiring 
scatter correction factors at 20 mm and 60 mm from the 
source of 0.0% and 0.4% for Ir-192 and 0.0% and 0.2% for Co-
60, respectively. This is a practical maximum size for 
convenient transportation. 
Table 1: Comparison of MCNP5 dose calculation with and 
without EBT3 film between source and tally cell, in water 
phantom. 
 
 
Figure 1: MCNP5 calculated scatter correction for Ir-192 and 
Co-60 HDR sources in spherical water phantoms of radii 100 
to 400 mm. 
 
Conclusions: Monte Carlo calculations using MCNP5 were 
conducted to support HDR brachytherapy dosimetry audit and 
QC measurements. It was confirmed Gafchromic EBT3 film 
does not disturb dose distributions compared to water-only 
cases. An optimum phantom size of 400 mm side cube was 
proposed with a maximum 0.4% scatter correction at 60 mm 
from the source. This data has been utilised in an IPEM 
dosimetry audit in the UK and may be applied in other 
brachytherapy dosimetry situations.  
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Purpose/Objective: To develop device with accuracy class 
0.02 mm for measuring the source-to-ionization chamber 
distance and to perform absolute calibration for the dose 
rate from the brachytherapy Ir-192 source at the distance ~ 4 
cm. 
Materials and Methods: As a basic measuring instrument was 
taken device with measuring tip, which virtual image, 
reflection in mirror of any 'base plane', enables to perform 
